

## Article Corrected

Mukonzo JK, Nanzigu S, Rekić D, Waako P, Röshammar D, Ashton M, Ogwal-Okeng J, Gustafsson LL, Aklillu E. HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 2011; 50 (8): 531-40

## Correction Made

**Page 539, column 1, ‘Acknowledgements’ section:** This section, which previously read:

“This study was funded by Swedish International Development Cooperation Agency Department for Research Cooperation (SIDA/SAREC) grant nos. SWE 2004-098, HIV-2006-031 and SWE 2007-270; the Makerere University-Karolinska Institutet research collaboration; and European and Developing Countries Clinical Trials Partnership (EDCTP) grant no. CT.2005.32030.001.

Daniel Röshammar is an employee of AstraZeneca. However, this work was not funded or supported by any pharmaceutical company. All authors have no conflicts of interest that are directly relevant to the content of this study.”

has now been corrected as follows:

“Jackson K. Mukonzo and Sarah Nanzigu contributed equally to this work.

This study was funded by Swedish International Development Cooperation Agency Department for Research Cooperation (SIDA/SAREC) grant nos. SWE 2004-098, HIV-2006-031 and SWE 2007-270; the Makerere University-Karolinska Institutet research collaboration; and European and Developing Countries Clinical Trials Partnership (EDCTP) grant no. CT.2005.32030.001.

Daniel Röshammar is an employee of AstraZeneca. However, this work was not funded or supported by any pharmaceutical company. All authors have no conflicts of interest that are directly relevant to the content of this study.”

## Note

All online versions of this article have been updated to reflect this correction.